BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 20547734)

  • 1. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.
    Koole C; Wootten D; Simms J; Valant C; Sridhar R; Woodman OL; Miller LJ; Summers RJ; Christopoulos A; Sexton PM
    Mol Pharmacol; 2010 Sep; 78(3):456-65. PubMed ID: 20547734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.
    Koole C; Wootten D; Simms J; Valant C; Miller LJ; Christopoulos A; Sexton PM
    Mol Pharmacol; 2011 Sep; 80(3):486-97. PubMed ID: 21616920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.
    Koole C; Wootten D; Simms J; Savage EE; Miller LJ; Christopoulos A; Sexton PM
    J Biol Chem; 2012 Feb; 287(6):3659-73. PubMed ID: 22147709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.
    Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
    J Pharmacol Exp Ther; 2015 Apr; 353(1):52-63. PubMed ID: 25630467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.
    Wootten D; Simms J; Koole C; Woodman OL; Summers RJ; Christopoulos A; Sexton PM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):540-50. PubMed ID: 21075839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
    Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
    Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
    Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
    Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
    Cheong YH; Kim MK; Son MH; Kaang BK
    Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
    Swedberg JE; Schroeder CI; Mitchell JM; Fairlie DP; Edmonds DJ; Griffith DA; Ruggeri RB; Derksen DR; Loria PM; Price DA; Liras S; Craik DJ
    J Biol Chem; 2016 Jul; 291(30):15778-87. PubMed ID: 27226591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
    J Biol Chem; 2012 Feb; 287(6):3642-58. PubMed ID: 22147710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
    Morris LC; Days EL; Turney M; Mi D; Lindsley CW; Weaver CD; Niswender KD
    J Biomol Screen; 2014 Jul; 19(6):847-58. PubMed ID: 24525870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.
    Coopman K; Huang Y; Johnston N; Bradley SJ; Wilkinson GF; Willars GB
    J Pharmacol Exp Ther; 2010 Sep; 334(3):795-808. PubMed ID: 20507928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
    López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
    J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
    Nakane A; Gotoh Y; Ichihara J; Nagata H
    Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
    Li N; Lu J; Willars GB
    PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery.
    Harikumar KG; Wootten D; Pinon DI; Koole C; Ball AM; Furness SG; Graham B; Dong M; Christopoulos A; Miller LJ; Sexton PM
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):18607-12. PubMed ID: 23091034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
    Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.